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There is an increasing realisation that the quality of the
biomacromolecular structures deposited in the Protein Data
Bank (PDB) archive needs to be assessed critically using
established and powerful validation methods. The Worldwide
Protein Data Bank (wwPDB) organization has convened
several Validation Task Forces (VTFs) to advise on the
methods and standards that should be used to validate all of
the entries already in the PDB as well as all structures that will
be deposited in the future. The recommendations of the X-ray
VTF are currently being implemented in a software pipeline.
Here, ongoing work on this pipeline is brieﬂy described as
well as ways in which validation-related information could be
presented to users of structural data.
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1. Introduction
The Protein Data Bank (PDB) is the single global repository
of experimentally determined three-dimensional structure
data on biomacromolecules and their complexes. Since 2003,
the PDB has been operated by the Worldwide Protein Data
Bank (wwPDB; http://wwpdb.org; Berman et al., 2007), which
consists of the RCSB PDB (Berman et al., 2000), PDBe
(Velankar et al., 2010, 2011, 2012), PDBj (Standley et al., 2008)
and BMRB (Ulrich et al., 2008). The four partners accept and
curate depositions of newly determined structures and the
corresponding experimental data and make these available in
the PDB archive. They also carry out remediation of the
archive, maintain a chemical component database, coordinate
the weekly releases of the archive, interact with journals and
deﬁne and implement procedures and standards for data
deposition and annotation. In addition, the wwPDB organi-
zation deﬁnes policy issues (e.g. regarding allowed hold
periods and mandatory deposition requirements), validation
standards and format speciﬁcations, with extensive input
from the community (through its advisory board or specially
convened task forces).
The structures in the PDB are based on a subjective inter-
pretation of experimental data, which may itself be of variable
quality, a process that can lead to errors with varying degrees
of impact (Bra ¨nde ´n & Jones, 1990; Morris et al., 1992; Kley-
wegt & Jones, 1995, 1996, 1997, 2002; Hooft et al., 1996;
Kleywegt, 2000, 2007, 2009; Chen et al., 2010). For this reason,
it is crucial to assess the quality and reliability of the resulting
models, a process known as validation (Kleywegt, 2000, 2009).
In the area of protein X-ray crystallography, a wealth of
experience has been gained in validation of models,
experimental data and the ﬁt of the model to these data.Unfortunately, the application of validation procedures by
practising crystallographers has been anything but uniform. In
the past decade the amount of structural data archived in the
PDB has grown enormously and these data now provide a rich
source of information for validation procedures, including
examples of various types of errors, a large population sample
to estimate a priori expectations and test sets for methods
development. Simultaneously, a number of unfortunate cases
in which published high-proﬁle structures turned out to be
seriously ﬂawed (e.g. Chang et al., 2006) have received wide-
spread attention, undermining the conﬁdence of user
communities in the reliability of three-dimensional structural
data in general (Miller, 2006, 2007).
A few years ago, the wwPDB partners realised that there
was both a need and an opportunity to consolidate the accu-
mulated experience and expertise in the area of validation of
X-ray crystal structures of biomacromolecules. They convened
a Validation Task Force (VTF) consisting of experts in the
ﬁeld to provide a set of community consensus recommenda-
tions on how to validate X-ray structures upon deposition in
the PDB and how to present the results of the validation to
the depositor. This wwPDB X-ray VTF (http://wwpdb.org/
workshop/2008) has recently published its report with ﬁndings
and recommendations (Read et al., 2011). The wwPDB
partners have also convened an NMRVTF (http://wwpdb.org/
workshop/2010/nmr_validation.html), which is expected to
produce an initial set of recommendations early in 2012. PDBe
and RCSB PDB, the two organizations who manage the
EMDB archive (Lawson et al., 2011), have also convened
a VTF for three-dimensional electron microscopy (3DEM;
http://vtf.emdatabank.org/; Henderson et al., 2012). Additional
task forces will inform the wwPDB partners in the future
about small-angle scattering techniques and hybrid methods
for structure determination.
The goals of structure validation for the PDB are as follows.
(i) To improve the quality and consistency of the structural
archive ‘at the gate’. Based on an in-depth report on the
quality and quirks of a model, a depositor may identify
problems that need further attention, such as limited
rebuilding and reﬁnement of a ligand or loop.
(ii) To support editors and referees of papers describing
structural data. To this end, the PDB validation reports should
contain summary information that compares the quality of a
model with that of other models in the archive.
(iii) To help expert and non-expert users of individual
released PDB entries to assess their quality and to decide
whether the entry is suitable for their needs (e.g. docking
studies, homology modelling, design of mutants or use as a
molecular-replacement probe).
(iv) To help expert and non-expert users to compare a
number of related PDB entries in order to identify the model
that appears to be of the highest quality among them
(Velankar & Kleywegt, 2011). A typical human protein in the
PDB today will occur in several dozen distinct PDB entries:
these will be structures determined by different techniques,
in different laboratories, under different conditions, with
different mutations and with different ligands. Identifying
‘the best’ of these models is a time-consuming challenge for
experts and nigh impossible for non-experts at present.
(v) To enable advanced users to identify and reject outliers
(in terms of structural quality) when mining or analysing the
entire archive or a substantial subset of it.
(vi) To stimulate the adoption of widely accepted state-
of-the-art validation methods (and possibly structure-
determination protocols) by the community.
Here, we describe our ongoing work on implementing the
recommendations of the X-ray VTF (Read et al., 2011) in a
software pipeline. We also describe how validation-related
information could be presented to users of structural data. For
more general reviews of the types of errors that can occur in
protein crystal structures as well as of validation methods that
can be used to detect (some of) these, we refer to the literature
(Bra ¨nde ´n & Jones, 1990; Kleywegt & Jones, 1995, 1996, 1997,
2002; Kleywegt, 2000, 2007, 2009).
2. A validation pipeline for the PDB
In 2011, the wwPDB X-ray VTF produced a detailed report
with recommendations on how to carry out validation of X-ray
data, models and the ﬁt of the models to the data (Read et al.,
2011).
Previous checking methods used by wwPDB deposition
sites were limited in their scope, e.g. Ramachandran analysis
(Kleywegt & Jones, 1996) and comparison of bond lengths
and bond angles to the statistics compiled by Engh & Huber
(1991). The checks proposed by the X-ray VTF are more
comprehensive and use contemporary methods and under-
lying distributions. For diffraction data, the recommended
checks include assessment of the Wilson plot, identiﬁcation
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Figure 1
Mock-up of a slider graph designed to convey information about key
validation criteria for an existing PDB entry or a new deposition.
Absolute percentile scores reﬂect how well the structure scores on the
corresponding criteria compared with all PDB entries. Relative percentile
scores show how it compares with structures determined at similar
resolution. (Figure kindly provided by Jane Richardson.)of outlier reﬂections, amplitude/intensity mislabelling, aniso-
tropy, twinning, missed symmetry etc.; these checks can be
carried out with the phenix.xtriage program (Adams et al.,
2010). Validation of models should include assessment of the
covalent geometry as well as of backbone and side-chain
torsion-angle combinations (Ramachandran and rotamer
analysis), possible ﬂipping of side chains, van der Waals
overlaps using a model that includes (riding) H atoms, un-
satisﬁed hydrogen-bond donors and acceptors etc. These
checks can be carried out with MolProbity (Chen et al., 2010)
and WHAT_CHECK (Hooft et al., 1996). For assessing the
agreement between the model and data, the VTFrecommends
the use of R and Rfree (Bru ¨nger, 1992) as global parameters
and per-residue assessment of the real-space R value (RSR;
Jones et al., 1991) by calculating RSR-Z scores as is performed
by the Uppsala Electron-Density Server (EDS; Kleywegt et
al., 2004). Some of the statistics will need to be calculated or
aggregated per residue, per chain or for the whole entry (e.g.
individual Ramachandran outliers are important, but also the
percentage of outliers for each individual protein chain and
for the entry as a whole).
To facilitate interpretation of the quality scores and
comparison of an entry with other structures, the X-ray VTF
recommends calculating percentile ranks for a number of key
statistics. The advantage of this is that users would not need to
know what the various statistics represent or what the ‘raw’
values mean. The percentile scores could be relative to the
entire archive (i.e. compared with all other X-ray structures in
the PDB) or to a subset of entries (e.g. compared with the 1000
X-ray structures with the most similar resolution). The former
would be most useful for users of PDB data and the latter
for depositors themselves as well as for journal editors
and referees. The VTF recommends
summarizing the percentile scores on
some key criteria using sliders (Fig. 1).
The VTF also made several recom-
mendations about the way in which the
results of the validation procedure could
be presented. After the validation has
been carried out, a human-readable
(PDF) report should be produced that
contains information that helps non-
experts assess the quality and alerts
experts (in particular, the depositor) to
unusual features that may require
further reﬁnement, rebuilding or veriﬁ-
cation. In addition, a machine-readable
ﬁle should be produced that can be used
by graphics software to guide model
analysis and rebuilding, and that can be
loaded into a database and used to drive
services that report and visualize
validation-related information to the
wider user community once a PDB
entry has been released.
Currently, the wwPDB partners are
developing a completely new software
system for deposition and annotation of structural data that,
once operational, will be used by all sites. Validation pipelines
for X-ray, NMR and EM models and data will form an integral
part of this new system. The implementation of the X-ray
validation pipeline is being carried out at the Protein Data
Bank in Europe (PDBe; http://pdbe.org). At a later stage, the
validation pipelines will also be made available as anonymous
web servers so that experimentalists will be able to assess the
quality of their models prior to deposition.
For practical reasons, the development of the X-ray vali-
dation pipeline is an incremental process. In the ﬁrst version, it
will include phenix.xtriage (Zwart et al., 2005) and components
of the EDS software (Kleywegt et al., 2004) to validate the
structure-factor data and the ﬁt of the model to the data. The
protein and nucleic acid components of the model itself will be
validated using components of MolProbity (Chen et al., 2010)
and WHAT_CHECK (Hooft et al., 1996). Finally, the
geometrical quality of ligand molecules will be assessed using
the program Mogul (Bruno et al., 2004), which will be
provided by the Cambridge Crystallographic Data Centre
(CCDC; http://www.ccdc.cam.ac.uk/products/csd_system/mogul).
An overview of the major components and input and output of
the pipeline is shown in Fig. 2.
The implementation of the X-ray validation pipeline is
carried out for each of the component modules in turn.
Initially, the contributed software is left intact as much as
possible, with the input provided in the expected formats (e.g.
PDB and MTZ ﬁles rather than the native mmCIF format that
is used by the new joint deposition and annotation system)
and the output ﬁltered to extract the relevant information.
Auxiliary software is developed as needed, e.g. to calculate
distributions and percentile ranks and to generate a PDF
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Figure 2
Overview of the components, input and output of the ﬁrst version of the wwPDB X-ray validation
pipeline that is currently being implemented following the recommendations of the wwPDB X-ray
Validation Task Force. In future versions of the pipeline, additional validation modules will be
included, e.g. WHAT_CHECK.report from the raw machine-readable validation-results ﬁle.
In some cases, methods will have to be modiﬁed or developed.
For example, RSR-Z score calculations as carried out by EDS
rely on average and standard deviation values for the common
amino-acid and nucleotide residues in different resolution
shells (Kleywegt et al., 2004). Since ligands often occur only
once or a few times in the PDB, no statistically meaningful
distribution is available for their RSR values. However,
ligands could be grouped based on the number of non-H
atoms that they contain and whether or not they contain
‘non-pharmaceutical’ atoms. Average RSR values and stan-
dard deviations could then be calculated in resolution shells
for entire groups of ligands of similar size and chemistry. We
are currently exploring the feasibility and effectiveness of this
novel approach.
The ﬁrst priority for our work on the X-ray validation
pipeline is to integrate it into the new wwPDB deposition and
annotation system and to implement it on the hardware of the
wwPDB partner sites. Once this has been achieved, we will
endeavour to make the pipeline available as a separate web-
based server as well. This would allow crystallographers to
assess the quality of intermediate models using the same
criteria that will be used upon deposition of the ﬁnal model,
and pinpoint any parts or aspects of the model that require
further attention.
A number of practical decisions will also have to be made.
Clearly, percentile ranks will change as more entries are
deposited in the PDB archive. For practical reasons, we intend
to produce a versioned PDB-wide list of validation statistics
annually, which will then be used to calculate the percentile
ranks for a year until the next version is released. These ﬁles,
as well as XML ﬁles with validation data for all released PDB
entries, will be made publicly available so that they can be
used by external software and database developers.
It is anticipated that the wwPDB X-ray VTF will reassess
the state-of-the-art in validation methodology occasionally
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Figure 3
Design mock-up of theuser interface of an enhanced version ofEDS currently under development at PDBe.This resource will present data (both overall
and per-residue) calculated by the wwPDB X-ray validation pipeline as well as interactive displays of models and electron-density maps. All the panels
are linked so that if residues are selected in onepanel they will be highlighted in all other panels as well. The buttons in the lower right corner can be used
to select subsets of residues, e.g. all Ramachandran plot outliers or all residues in the binding site of a certain ligand.(e.g. every ﬁve years) and adjust or augment its recommen-
dations accordingly.
The wwPDB partners hope that many journals will follow
the lead of the IUCr journals and begin to require submission
of the PDB validation report whenever a manuscript
describing a new biomacromolecular structure is submitted for
publication.
3. Presenting validation-related information to users
The wwPDB partners engage in friendly competition with
regard to the presentation of data from the PDB archive to
users and the development of value-added services and
resources. Hence, they are free to and will independently
develop methods to use the validation data for released
entries and present it to users.
As described previously (Velankar & Kleywegt, 2011),
PDBe intends to assimilate the EDS functionality and inte-
grate it into its data infrastructure. The functionality of EDS
will be enhanced by adding data produced by the wwPDB
validation pipeline to provide a comprehensive analysis of the
quality and reliability of crystal structures. Fig. 3 shows a
mock-up of what such a resource could look like for a released
PDB entry. The EDS software has been re-implemented and
will provide electron-density maps; the wwPDB validation
facility described above will provide a host of additional
quality information. In the current design plans, the service
will display linked views of the model and electron-density
maps as well as one-dimensional plots (e.g. RSR-Z scores per
residue) and two-dimensional graphs (e.g. Ramachandran
plot) and an information panel. Whenever a residue is selected
in any of the views or graphs, it will become active in all others
as well. There will also be a mechanism to select ‘interesting’
subsets of residues, e.g. residues in a ligand-binding site or all
Ramachandran outliers.
Finally, as and when the recommendations of the NMR and
3DEM VTFs are implemented, PDBe will also develop
services to facilitate validation and analysis of the models
produced by these techniques. A ﬁrst glimpse of what could be
performed with respect to analysis and validation of NMR
entries is available as a PDBe service called Vivaldi (http://
pdbe.org/vivaldi; Velankar et al., 2012).
4. Concluding remarks
As the various subdisciplines of molecular and cellular struc-
tural biology mature, we expect that a consensus about
sensible and informative validation methods will emerge. It
took the ﬁeld of protein X-ray crystallography some 25 years
to go through this, at times painful, process. In the mid-1980s
it was ﬁrst realised that crystallographic models could occa-
sionally be signiﬁcantly in error (Bra ¨nde ´n & Jones, 1990); now,
the community has ﬁnally agreed that deposition of models
and data, as well as validation of both, should be mandatory
for every new structure that is archived in the PDB.
It is the professional obligation of every structural biologist
to produce the best possible models that are supported by
their experimental data and to teach their students and
colleagues how to achieve this (Bra ¨nde ´n & Jones, 1990;
Kleywegt, 2000; Kleywegt et al., 2004; Rupp, 2010). In addi-
tion, it is important that the community as a whole promotes
a basic understanding among non-experts of how structures
come about, the fact that sometimes errors are made and how
validation methods can help to pinpoint problems in indivi-
dual models and enable users to select the most appropriate
model.
The wwPDB partners are committed to utilizing established
validation methods to improve the quality and integrity of
the archive and to enabling users of structural data to make
informed choices about the most suitable models for their
purposes, without requiring them to become experts in any
structure-determination method or even in validation
methodology.
We wish to express our gratitude to all the members of the
wwPDB Validation Task Forces. The X-ray VTF had to break
a lot of new ground and undertook its quest enthusiastically
and thoroughly and came up with several innovative ﬁndings
and recommendations. Moreover, several of the VTF
members have made their validation software available for the
wwPDB X-ray validation pipeline. We further wish to thank
our collaborators on the wwPDB Deposition and Annotation
Project core team (Zukang Feng, Tom Oldﬁeld, Martha
Quesada, Sanchayita Sen, John Westbrook and Jasmine
Young) as well as Kim Henrick and Helen Berman who
established the X-ray VTF. We thank Jane Richardson for
providing the slider image (Fig. 1). Funding for the develop-
ment of the X-ray validation pipeline at PDBe is provided by
EMBL–EBI and the Wellcome Trust (grant 088944).
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